A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2011-7-2-84-87
Abstract
Prostate cancer (PC) is one of the most pressing problems of urologic cancer due to higher morbidity from this pathology worldwide. Treatment policy in PC patients is determined by the extent of a cancer process. Radical therapy for metastatic PC is impossible, hence this patient group is considered eligible for palliative hormonal or chemotherapy. To choose the optimal treatment for patients with hormone-refractory PS (HRPS) is an intricate problem regarding particularly patients with asymptomatic HRPS and those with progressive cancer after chemotherapy with docetaxel. In this instance, the treatment policy is a matter of discussion and is not well defined. The paper considers the use of somatostatin analogues as an alternative to drug therapy for patients with HRPS. Octreotide is one of the most popular drugs of this group. The agent may be used to treat patients with HRPS both before and after systemic cytotoxic therapy. Octreotide therapy is effective and safe; its side effects are minimal and it is well tolerated in patients.
About the Authors
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute
Department of Urology with a Course of Oncology, Russian Peoples’ Friendship University
Russian Federation
Russian Federation
A. D. Kaprin
Department of Urology with a Course of Oncology, Russian Peoples’ Friendship University
City Clinical Hospital Twenty, Moscow
Russian Federation
Russian Federation
K. M. Nyushko
P.A. Herzen Moscow Oncology Research Institute
Russian Federation
Russian Federation
References
1. Чиссов В.И., Старинский В.В. (ред.) Состояние онкологической помощи населению России в 2007 году. М., 2008; с. 106.
2. EAU Guidelines 2011; p. 130.
3. Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17(12):1733–42.
4. Pollak M.N., Schally A.V. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217(2):143–52.
5. Bogden A.E., Taylor J.E., Moreau J.P. et al. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res 1990;50(9):2646–50.
6. Verhelst J., De Longueville M., Ongena P. et al. Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg 1994;62(1):83–8.
7. Koutsilieris M., Mitsiades C.S., Bogdanos J. et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10(13):4398–405.
8. Dimopoulos M.A., Kiamouris C., Gika D. et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology 2004;63(1):120–5.
9. Mitsiades C.S., Bogdanos J., Karamanolakis D. et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 2006;26(5B):3693–700.
10. Alekseev B.Y., Rusakov I.G., Kaprin A.D. et al. Somatostatin analog in the treatment of androgen–independent prostate cancer before and after chemotherapy. Eur Ur Suppl 2010;9(2):284.
11. Алексеев Б.Я, Русаков И.Г., Kаприн А.Д. и др. Аналоги соматостатина в лечении гормонорефрактерного рака предстательной железы до и после химиотерапии. Материалы V конгресса онкоурологов. Москва, 6–8 октября 2010 г. С. 5–6.
Review
For citations:
Alekseev B.Ya., Kaprin A.D., Nyushko K.M. A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER. Cancer Urology. 2011;7(2):84-87. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-2-84-87
Views:
927
Email this article 